P Arnold1, S Jackson, J Wallis, J Smith, D Bolton, S Haynes. 1. Department of Anaesthesia, Alder Hey (Royal Liverpool Children's Hospital), Eaton Road, Liverpool L12 2AP, UK. p.d.arnold@ukonline.co.uk
Abstract
OBJECTIVE: To ascertain the activity of major coagulation factors during the first 24 h of extra-corporeal membrane oxygenation (ECMO) used to support hypoxaemic neonates. DESIGN AND SETTING: A prospective observational study in a regional centre for ECMO and paediatric cardiac surgery, placing 15-20 neonates on ECMO per year. PATIENTS: Ten neonates receiving ECMO for severe hypoxaemia. MEASUREMENT AND RESULTS: The activity of major clotting factors, of the inhibitor anti-thrombin III and of markers of blood activation were measured during the first 24 h of neonatal extra-corporeal membrane oxygenation (ECMO) and prior to initiation of ECMO. There was laboratory evidence of factor deficiency and of activation of coagulation at all stages. The initiation of ECMO leads to an initial worsening of coagulopathy, but factor deficiency and abnormal activation of coagulation is also seen prior to ECMO in these very sick neonates. CONCLUSION: If factor deficiency is to be avoided a pro-active approach is required to rapidly correct factor activity. This would include the use of fresh frozen plasma. The effect of such an approach on outcome is at yet uncertain.
OBJECTIVE: To ascertain the activity of major coagulation factors during the first 24 h of extra-corporeal membrane oxygenation (ECMO) used to support hypoxaemic neonates. DESIGN AND SETTING: A prospective observational study in a regional centre for ECMO and paediatric cardiac surgery, placing 15-20 neonates on ECMO per year. PATIENTS: Ten neonates receiving ECMO for severe hypoxaemia. MEASUREMENT AND RESULTS: The activity of major clotting factors, of the inhibitor anti-thrombin III and of markers of blood activation were measured during the first 24 h of neonatal extra-corporeal membrane oxygenation (ECMO) and prior to initiation of ECMO. There was laboratory evidence of factor deficiency and of activation of coagulation at all stages. The initiation of ECMO leads to an initial worsening of coagulopathy, but factor deficiency and abnormal activation of coagulation is also seen prior to ECMO in these very sick neonates. CONCLUSION: If factor deficiency is to be avoided a pro-active approach is required to rapidly correct factor activity. This would include the use of fresh frozen plasma. The effect of such an approach on outcome is at yet uncertain.
Authors: Kristina M Nelson; Lizbeth A Hansen; Marie E Steiner; Gwenyth A Fischer; John Dehnel; Sameer Gupta Journal: J Pediatr Pharmacol Ther Date: 2017 Jul-Aug
Authors: Gennaro Martucci; Artur Słomka; Steven Eric Lebowitz; Giuseppe Maria Raffa; Pietro Giorgio Malvindi; Valeria Lo Coco; Justyna Swol; Ewa Żekanowska; Roberto Lorusso; Waldemar Wierzba; Piotr Suwalski; Mariusz Kowalewski Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Jill M Cholette; Jennifer A Muszynski; Juan C Ibla; Sitaram Emani; Marie E Steiner; Adam M Vogel; Robert I Parker; Marianne E Nellis; Melania M Bembea Journal: Pediatr Crit Care Med Date: 2022-01-01 Impact factor: 3.971
Authors: Melania M Bembea; Gail Annich; Peter Rycus; Gary Oldenburg; Ivor Berkowitz; Peter Pronovost Journal: Pediatr Crit Care Med Date: 2013-02 Impact factor: 3.624
Authors: Melania M Bembea; Jamie M Schwartz; Nilay Shah; Elizabeth Colantuoni; Christoph U Lehmann; Thomas Kickler; Peter Pronovost; John J Strouse Journal: ASAIO J Date: 2013 Jan-Feb Impact factor: 2.872
Authors: Sendhil K Balasubramanian; Ravindranath Tiruvoipati; Mohammed Amin; Kanakkande K Aabideen; Giles J Peek; Andrew W Sosnowski; Richard K Firmin Journal: J Cardiothorac Surg Date: 2007-01-11 Impact factor: 1.637